New York GDOL and Cancer Moonshot Summit: A Winning Combination
The LRG 2016 GIST Days of Learning Tour (GDOL) made a stop in New York City on June 29th. A GIST Day of Learning is a free, one-day program that provides both education and [...]
Fundación GIST Chile GIST Awareness Day Video
On the GIST Awareness Day, Fundación GIST Chile wants to be the voice of all people who require that Health Systems cover the treatments that we need.
Life Fest 2016 – Monica Anderson – Story of Hope
Dr. Monica Anderson inspires us through sharing her own personal journey of health challenges to surviving, thriving and loving life at Life Fest 2016
GIST Day of Learning Portland 2016 Full Video
A GIST Day of Learning (GDOL) was held on March 30, 2016 at The Center for Health and Healing, OHSU Knight Cancer Institute, Portland Oregon. GDOL’s are smaller group events held throughout the [...]
LOXO-101 receives breakthrough therapy designation from FDA for solid tumors with NTRK gene fusions
Loxo Oncology announced in a press release that the FDA has granted breakthrough therapy designation to LOXO-101 for the treatment of unresectable or metastatic solid tumors with neurotrophic tyrosine receptor kinase gene fusions. This [...]
GDOL New York City 2016 Photos
The GIST Day of Learning (GDOL) New York City was held on June 29th at the American Cancer Society. The Life Raft Group held a Regional Cancer Moonshot Summit combined with a GIST Day of Learning. The purpose [...]
Quadruple-Negative GIST Tumors May Be More Likely To Harbor NF1 Mutations As Well
In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]
Thoughts on the Cancer Moonshot Summit
On July 29, 2016 I traveled to Howard University in Washington, DC to be a participant in Vice President Joe Biden’s Cancer Moonshot Summit. This invitation-only event was designed to bring together individuals and [...]
Ignyta Announces Results for Potential New Cancer Treatment
Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]